Bioavailability of the antiemetic metopimazine given as a microenema

British Journal of Clinical Pharmacology

Volumn 41, Issue 6, 1996, Pages 613-615

  Herrstedt, Jørn ^a,d   Jørgensen, Morten ^a   Angelo, Helle Riis ^b   Rassing, Margrethe Rømer ^c   Møller Sonnergaard, Jørn ^c   Dombernowsky, Per ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d HILLERØD HOSPITAL   (Denmark)

Author keywords

antiemetics; bioavailability; enemas; metopimazine

Indexed keywords

ANTIEMETIC AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DRUG METABOLITE; ENEMA; METOPIMAZINE; PHENOTHIAZINE DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; SEDATION; SIDE EFFECT; VOMITING;

EID: 0029989837     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.35220.x     Document Type: Article

References (12)

1. 1-adrenergic receptors. Cancer Chemother Pharmacol 1993; 33: 53-56.
2. Israel L, Rodary C. Treatment of nausea and vomiting related to anticancerous multiple combination chemotherapy: results of two controlled studies. J Int Med Res 1978; 6: 236-40.
3. Moertel CG, Reitemeier RJ. Controlled studies of metopimazine for the treatment of nausea and vomiting. J Clin Pharmacol 1973; 57: 283-7.
4. Herrstedt J, Sigsgaard TC, Boesgaard M, Jensen TP, Dombernowsky P. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 1993; 328: 1076-80.
5. Herrstedt J, Jørgensen M, Angelo HR. The effect of food on serum concentrations of metopimazine. Br J Clin Pharmacol 1990; 30: 237-43.
6. Hoogdalem EJ Van, Boer AG de, Breimer DD. Pharmacokinetics of rectal drug administration, Part I: general considerations and applications of centrally acting drugs, Part II: clinical applications of peripherally acting drugs, and conclusions. Clin Pharmacokinet 1991; 21: 11-26 (Part I) and 110-28 (Part II).
7. Angelo HR, Herrstedt J, Jørgensen M. High-performance liquid chromatographic method with fluorescence detection for the simultaneous determination of metopimazine and its acid metabolite in serum. J Chromatogr 1989; 496: 472-477.
8. Gaillot J, Bieder A. Comportement metabolique de la metopimazine en fonction des voies d'administration. Incidence des effets de premier passage sur la biodisponibilite systemique. Il Farmaco 1980; 35: 3-22.
9. De Boer AG, Moolenaar F, De Leede LGJ, Breimer DD. Rectal drug administration: Clinical pharmacokinetic considerations. Clin Pharmacokinet 1982; 7: 285-311.
10. Bundgaard H. The prodrug approach for improved rectal delivery. In Novel drug delivery and its therapeutic application, eds Prescott LF & Nimmo WS. J Wiley & sons Ltd. Chichester, 1989: 193-208.
11. De Boer AG. 'First pass' elimination of some high-clearance drugs following rectal administration to humans and rats. Ph.D thesis (University of Leiden, The Nederlands 1979).
12. Rhone-Poulenc Report (data on file).